Form 8-K - Current report:
SEC Accession No. 0001493152-24-035508
Filing Date
2024-09-09
Accepted
2024-09-09 17:15:12
Documents
18
Period of Report
2024-09-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42912
2 ex4-1.htm EX-4.1 114343
3 ex4-2.htm EX-4.2 146293
4 ex10-1.htm EX-10.1 59512
5 ex99-1.htm EX-99.1 12548
  Complete submission text file 0001493152-24-035508.txt   625512

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE qlgn-20240906.xsd EX-101.SCH 3009
7 XBRL LABEL FILE qlgn-20240906_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE qlgn-20240906_pre.xml EX-101.PRE 24161
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3692
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 241287995
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)